1. Kennedy, LB, Salama, AKS. A review of cancer immunotherapy toxicity. CA Cancer J Clin Mar 2020; 70: 86–104.
Google Scholar | Crossref | Medline2. Esfahani, K, Roudaia, L, Buhlaiga, N, et al. A review of cancer immunotherapy: from the past, to the present, to the future. Curr Oncol Apr 2020; 27: S87–S97.
Google Scholar | Crossref | Medline3. Liu, YH, Zang, XY. Wang, JC , et al. Diagnosis and management of immune related adverse events (irAEs) in cancer immunotherapy. Biomed Pharmacother Dec 2019; 120: 109437.
Google Scholar | Crossref | Medline4. Thompson, JA . New NCCN guidelines: recognition and management of immunotherapy-related toxicity. J Natl Compr Canc Netw May 2018; 16: 594–596.
Google Scholar | Crossref | Medline5. Wang, PF, Chen, Y, Song, SY, et al. Immune-Related adverse events associated with anti-PD-1/PD-L1 treatment for malignancies: a meta-analysis. Front Pharmacol Oct 2017 18; 8: 30.
Google Scholar | Medline6. Sher, AF, Golshani, GM, Wu, S. Fatal adverse events associated with pembrolizumab in cancer patients: a meta-analysis. Cancer Invest Feb 2020 ; 38: 130–138.
Google Scholar | Crossref | Medline7. Naranjo, CA, Busto, U, Sellers, EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther Aug 1981; 30: 239–245.
Google Scholar | Crossref | Medline8. Eun, Y, Kim, IY, Sun, JM, et al. Risk factors for immune-related adverse events associated with anti-PD-1 pembrolizumab. Sci Rep Oct 2019 1; 9: 14039.
Google Scholar | Crossref | Medline9. Puzanov, I, Diab, A, Abdallah, K, et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the society for immunotherapy of cancer (SITC) toxicity management working group. J Immunother Cancer Nov 2017 21; 5: 95.
Google Scholar | Crossref | Medline10. Nishino, M, Sholl, LM, Hodi, FS, et al. Anti-PD-1-Related pneumonitis during cancer immunotherapy. N Engl J Med Jul 2015 16; 373: 288–290.
Google Scholar | Crossref | Medline11. Haanen, JBAG, Carbonnel, F, Robert, C, et al. Management of toxicities from immunotherapy: eSMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. Jul 1 2017;28(suppl_4): iv119–iv142.
Google Scholar | Medline12. Mandalà, M, Merelli, B, Indriolo, A, et al. Late-occurring toxicity induced by an immune checkpoint blockade in adjuvant treatment of a stage III melanoma patient. Eur J Cancer May 2018; 95: 130–132.
Google Scholar | Crossref | Medline13. Khan, OF, Monzon, J. Diagnosis, monitoring, and management of adverse events from immune checkpoint inhibitor therapy. Curr Oncol. 2020 Apr;27(Suppl 2): S43–S50.
Google Scholar | Medline14. Belum, VR, Benhuri, B, Postow, MA, et al. Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor. Eur J Cancer Jun 2016; 60: 12–25.
Google Scholar | Crossref | Medline15. Baxi, S, Yang, A, Gennarelli, RL, et al. Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis. Br Med J Mar 14 2018; 360: k793. k793.
Google Scholar | Medline16. Champiat, S, Lambotte, O, Barreau, E, et al. Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. Ann Oncol Apr 2016; 27: 559–574.
Google Scholar | Crossref | Medline17. Callahan, M, Yang, A, Tandon, S, et al. Evaluation of serum IL-17 levels during ipilimumab therapy: correlation with colitis. J Clin Oncol. 2011 29:15_suppl, 2505–2505.
Google Scholar | Crossref18. Schindler, K, Harmankaya, K, Kuk, D, et al. Correlation of absolute and relative eosinophil counts with immune-related adverse events in melanoma patients treated with ipilimumab. J Clin Oncol.2014.32.15_suppl.9096.
Google Scholar | Crossref19. Berman, D, Parker, SM, Siegel, J, et al. Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanoma. Cancer Immun Nov 24 2010; 10: 11.
Google Scholar | Medline20. Oh, DY, Cham, J, Zhang, L, et al. Immune toxicities elicted by CTLA-4 blockade in cancer patients Are associated with early diversification of the T-cell repertoire. Cancer Res Mar 15 2017 ; 77: 1322–1330.
Google Scholar | Crossref | Medline21. Fukihara, J, Sakamoto, K, Koyama, J, et al. Prognostic impact and risk factors of immune-related pneumonitis in patients with Non-small-cell lung cancer Who received programmed death 1 inhibitors. Clin Lung Cancer Nov 2019; 20: 442–450. e4. doi: 10.1016/j.cllc.2019.07.006.
Google Scholar | Crossref | Medline22. Toi, Y, Sugawara, S, Sugisaka, J, et al. Profiling preexisting antibodies in patients treated with anti-PD-1 therapy for advanced Non-small cell lung cancer. JAMA Oncol Mar 1 2019; 5: 376–383.
Google Scholar | Crossref | Medline